Biosimilars: how similar?-Reference-Cited by-同舟云学术

Biosimilars: how similar?

Published:2014-03 Issue:3 Volume:44 Page:218-223
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Strand V.¹,Cronstein B.²

Affiliation:

1. Biopharmaceutical Consultant; Portola Valley California USA

2. Divisions of Translational Medicine and Rheumatology; NYU School of Medicine; New York USA

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.12292/fullpdf

Reference33 articles.

1. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know;Strober;J Am Acad Derm,2012

2. Biosimilars: what clinicians should know;Weise;Blood,2012

3. The role of biosimilars in the treatment of rheumatic diseases;Dörner;Ann Rheum Dis,2013

4. Biosimilars in rheumatology: the wind of change;Schneider;Ann Rheum Dis,2013

5. European Medicines Agency European Medicines Agency recommends approval of first two monoclonal antibody biosimilars http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006);Current Medical Research and Opinion;2022-04-17

2. Biosimilars in der pädiatrischen Rheumatologie;Pädiatrische Rheumatologie;2022

3. Biosimilars in der pädiatrischen Rheumatologie;Pädiatrische Rheumatologie;2021

5. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations;Current Medicinal Chemistry;2019-03-14